Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

chieved during fiscal 2008, we have strengthened our financial position through a $6.9 million non-dilutive financing by means of corporate reorganization and initiation of a rights offering. The achievements realized this year have resulted in a necessary increase in research and development expenditures, although we expect our overall expenditures to decrease significantly in fiscal 2009".

FINANCIAL RESULTS

Due to an increase in research and development activities as described below, loss from operations excluding the gain on sale relating to the arrangement (as discussed below) for the year ended May 31, 2008, increased to $12.6 million from $9.6 million in the same period last year. On the close of the arrangement, in July 2007, the Company realized a gain on the sale of the shares of Old Lorus in the amount of $6.3 million resulting in a net loss for the year ended May 31, 2008 of $6.3 million ($0.03 per share).

Research and development expenses increased to $6.1 million for the year ended May 31, 2008 as compared $3.4 million in the prior year.

The increase in research and development expenditures in the year ended May 31, 2008 is due to a significant increase in activity within our LOR-2040 and Small Molecule development programs, in particular, due to the manufacturing cost of LOR-2040 needed to complete the ongoing Phase I and Phase II clinical studies as well as future potential development initiatives. Other contributing factors include the initiation of an advanced Phase II clinical trial with LOR-2040 in AML, GLP-toxicology studies with LOR-2040 for the treatment of bladder cancer, and the advancement of our small molecule program into GLP-toxicology studies.

For the year ended May 31, 2008, general and administrative expense was $3.9 million compared with $3.8 million in the same period last year. General and administrative expenditures have remained consistent with the prior year.

The Company utilized cash of
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 29, 2014 Transparency Market Research, in ... SPPS, LPPS, HPPS, by Application - Cancer, Metabolic, CVS, ... and by Delivery) - Global Industry Analysis, Size, Share, ... the global peptide therapeutics market was worth US$14.1 billion ... by 2018 at an 8.7% CAGR. , The two ...
(Date:9/29/2014)... , Sept. 29, 2014 Burnham Securities ... Channel Group ("TCG"), a leader in healthcare venture ... formed an alliance to expand the range of ... With the alliance, Burnham Securities will be supported ... clinical medicine and management in healthcare industry to ...
(Date:9/29/2014)... 2014 Latest study ... transform network connectivity as customers put quality and ... ProLabs , the leading independent provider of global ... of their survey conducted at the 2014 European ... communications professionals from across the globe. ...
(Date:9/29/2014)... 29, 2014  Perrigo Company plc (NYSE: ... has transferred a portfolio of preclinical research assets, ... of Elan Corporation plc, to drug discovery and ... agreement, Perrigo will receive an upfront payment in ... on any future sales derived from the portfolio. ...
Breaking Biology Technology:Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3End of an Era: OEM Dominance - Could it be a Thing of the Past? 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4
... 29 Tutogen Medical, Inc.,(Amex: TTG ), a ... (allograft) and animal (xenograft) tissue, announced today,that Guy L. ... the Roth Capital Partners New York Investor Conference on,Thursday, ... conference is,being held at The Westin NY at Times ...
... N.Y., Aug. 29 Emisphere,Technologies, Inc. (Nasdaq: ... been appointed to the position of Chief Financial ... CFO and Interim Chief Executive Officer,of Astralis, Ltd., ... Michael V. Novinski, President and Chief Executive Officer. ...
... PHRM ) today announced that the U.S. ... designation for oral Azacitidine in the,treatment of Myelodysplastic ... to facilitate the development and,expedite the review of ... or,life-threatening conditions and that demonstrate the potential to ...
Cached Biology Technology:Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6
(Date:9/29/2014)... article published online in Behavioral Brain Research ... brain as a result of chronic alcohol exposure that ... , Clinical assessments and research indicate that individuals with ... This can occur when people are actively drinking, when ... abstaining. , "Sleep-wake disturbances can last for months, ...
(Date:9/29/2014)... when the supercontinent of Pangea was starting to break up ... kinds of reptiles called phytosaurs and rauisuchids were at the ... the two top predators didn,t interact much as the former ... land. But those ideas are changing, thanks largely to the ... online in September in the German journal Naturwissenschaften ...
(Date:9/29/2014)... Growing Demand From Huge ... Security Concerns Continue to Propel Biometrics Market in ... is one of the fastest growing biometrics markets ... majorly in various government projects such as National ... biometrics dominates the country,s biometrics market, with other ...
Breaking Biology News(10 mins):Tooth buried in bone shows prehistoric predators tangled across land, sea 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
... flat. Even the flattest of basement membranes has topography; ... , Unlike the princess kept awake by the ... cultured on a substrate deliberately printed with nanoscale ... of Wisconsin–Madison. , The researchers used soft ...
... been stopped early due to preliminary results indicating that ... HIV during heterosexual intercourse by 53 percent. , The ... 12 to review the interim data. Based on the ... trial and recommended that all men enrolled in the ...
... Give or take a few dozen trillions, a human adult ... roundworm has exactly 959 cells. , Yet we have ... University, who has been exploring two “highly conserved? cell-signaling pathways ... we have a lot of common enemies, particularly soil-borne ...
Cached Biology News:Embryonic stem cells do better on bumpy nanoscale mattress 2Male circumcision reduces HIV risk, study stopped early 2Male circumcision reduces HIV risk, study stopped early 3Worms produce surprise insight into human fever 2
...
... The new IKATUBE ULTRA TURRAX Tube Disperser System ... homogenizing system. It offers a cleaner, safer, and ... system processes sample volumes from 2 to 15 ... type, researchers can choose one of 4 different ...
...
... Triple-angle light scattering detector for ... digital signal processing hardware for two ... UV detectors. Also contains an analog ... interfacing to strip chart recorders. Includes ...
Biology Products: